The global bioabsorbable stent market is anticipated to grow from $ 251 million in 2016 to $689 million by 2025, at a CAGR of 11.86% between 2016 and 2025. The bioabsorbable stents are the devices inserted into the blood vessel or other internal duct that enlarges the vessel to check or alleviate a blockage. These stents are made up of materials may be absorbed or dissolved in the body. A large number of benefits provided by the bioabsorbable stents makes it beneficial over the earlier technologies present in the field. The bioabsorbable stent market is primarily driven by following factors:

• Rise in incidence of cardiac diseases
• Increasing risk of coronary artery & peripheral artery diseases in the elderly population
• Increasing number of heart failure and diabetes cases
• Strong product pipelines
• Rising technological advancements
• Increasing diabetic population

To learn more about this report, request a free sample copy

The important driver increasing growth in the global bioabsorbable stent market is the rising incidence of cardiac diseases worldwide, with cardiac arrests being the foremost reason of demise among entities aged 60 years and above. According to CDC, cardiac illnesses accounted for over 0.45 million death in the US each year. Hypertension is the most mutual motive for heart failure and is instigated due to an upsurge in the blood pressure in the arteries causes an imperative risk issue for various CVDs like stroke, CAD, heart failure, and PVD.

The Applications, materials and the drugs of bioabsorbable stent market are used extensively for various purposes. CAD is a cardiovascular condition in which a waxy substance called plaque builds up inside the coronary arteries. PAD is a disorder of blood circulation that causes the narrowing of blood vessels of the heart and the brain. Polymers have found wide applications in cardiology, specifically in coronary vascular intervention as scaffolds (stent platforms) and coating matrices for drug-eluting stents. Bioabsorbable metallic stents consist of either iron-based (Fe) or magnesium based alloys (Mg). Paclitaxel refers to a taxane derivative along with antiproliferative properties that makes it effective in treating coronary restenosis. Numerous members of litmus family are deployed as the drug component of eluting drug stents including zotarolimus, sirolimus, and everolimus.

Slow adoption rate and stringent government regulations are the major factors hindering the bioabsorbable stent market. Many stents under trial, slow approval from FDA and less commercial availability of the stent is impacting the recognition of the bioabsorbable stent market. Cost is also a major issue for the bioabsorbable stent market. Few complex issues associated with DES contain the length of clinical trials to define safety and the suitable dosage and period of attendant antiplatelet therapy. The FDA admits that DES are difficult products to produce and there are high safety issues in the stents.

The global bioabsorbable stent market segments include absorption rates, drugs, applications, end-users, and materials.

Absorption rates are segmented into:

• Slow absorption stents
• Fast absorption stents

Drugs are segmented into:

• Paclitaxel
• Limus based drugs

Applications are segmented into:

• Coronary artery disease
• Peripheral artery disease

End users are segmented into:

• Hospitals
• Cardiac centers

Materials are segmented into:

• Polymeric Stents
• Metallic Stents

This report covers the present market conditions and the growth prospects of the global bioabsorbable stent market for 2017-2025 and considered the revenue generated through the sales of the bioabsorbable stent for absorption rates, drugs, applications, end-users, and materials to calculate the market size considering 2016 as the base year.

Geographically, the global bioabsorbable stent market has been segmented on the basis of four major regions, which include:

• North America– Canada, United States & Mexico
• Asia-Pacific– India, Japan, China, South Korea & Rest of APAC
• Europe– UK, Spain, Germany, France, Italy & Rest of Europe
• Rest of World- the Middle East, Latin America, South Africa

The bioabsorbable stent market in Europe is expected to hold the largest share by 2025 possibilities of increased adoption of technologically advanced products. Also, the increase in coronary and peripheral procedures in Europe has increased the demand of bioabsorbable stents. Heart failure has affected 23 million people globally, and Europe accounts for 10 million of them. The market in the European countries is witnessing growth due to growing adoption of MI surgeries, which enables faster recovery. On the other hand, Asia-Pacific market is anticipated to the fastest-growing region for the bioabsorbable stent market. According to a survey by United Nation Population Fund, by 2050, one in four people in Asia Pacific will be over 60 years old. The population of the older people in the region will triple reaching 1.3 billion, with women constituting the majority of over 53%. Aging population will aid the growth of the market during the forecasted period.

The bioabsorbable stent market is segmented on the basis of absorption rates which is sub-divided into slow absorption stents and fast absorption stents. The end users segment is sub-divided into hospitals and cardiac centers. Slow absorption stents are designed to slowly release the drug to cure coronary diseases which require the long-term treatment. The fast absorption stents are being used to cure the coronary arterial diseases where the requirement of the stents is on the urgent basis, and the stents dissolve in less time. The sirolimus-eluting stents are made of stainless steel platform that is coated with a polymer, the 80% of the drug is out within the 30 days of the implants. Hospitals have the advanced medical infrastructure and trained professionals to cater to the needs of people. There is a rise in the use of bioabsorbable stents due to the increase in the number of cardiovascular procedures carried out at the hospitals. Cardiac centers refer to the specialized area where particularly cardiac disease patients are diagnosed & treated and cover all the aspects from imaging tests to the surgical procedures.

The major market players in the global bioabsorbable stent market are:

• ABBOTT LABORATORIES
• ARTERIAL REMODELING TECHNOLOGIES
• BOSTON SCIENTIFIC CORP.
• JOHNSON & JOHNSON
• MEDTRONIC INC

Company Profiles covers analysis of important players.

Abbott Laboratories (Abbott) is a US based company and is headquartered in Illinois. The company develops, manufactures, discovers, and sells a broad and diversified line of healthcare products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors. Medtronic, Inc. (Medtronic) a US-based medical technology company headquartered in Minnesota. The companies generated a US$ 20,261 million revenue in 2015 and have 85000 employees that aids to full fill the mission and goals of the company. The company develops, manufacture and market a wide range of medical devices, therapies, and services used in the treatment of chronic conditions such as diabetes, vascular disease, neurological disorders, spinal conditions and heart disease.

Key Findings of the Global Bioabsorbable stent market:

• Bioabsorbable stents are used in a wide range of applications
• Growing incidence of CVDS
• Polymeric stents market is anticipated to grow at a faster rate
• Coronary artery disease holds the largest market share